Latest News

Johns Hopkins Hospital Study Data To Be Presented At USCAP 2018 08-Nov-2017

An abstract discussing the results of a study performed by researchers at Johns Hopkins Ho.. READ MORE

Appendix 4C – Quarterly Cash Flow Report 18-Oct-2017

The cash balance at 30 September was $4.1 million, with net cash inflow for the quarter totallin.. READ MORE

Exclusive Distributor Appointed for Denmark and Sweden 25-Sep-2017

Melbourne, Australia, 25 September 2017: Sienna Cancer Diagnostics, a commercial stage, medical .. READ MORE

Investor Information

Sienna is a public unlisted company headquartered in Melbourne, Australia. In January 2015, Sienna transitioned from a purely Research and Development company to a true commercial entity with product revenues. The company has approximately 160 shareholders and is governed by an experienced board and management team, Sienna has benefited from over $5.7M in R&D Tax Incentive refunds and government grant programs, significantly bolstering investor contributions and facilitating the progress and growth to date. READ MORE

Research

Sienna’s core activities have historically focused on the clinical translation of biomarkers using novel diagnostic technologies for applications in pathology laboratories. The development of inexpensive, high performing in vitro diagnostic tests is expected to lead to radical changes in the approach to care and assessment of cancer patients – a change welcomed by clinicians and governments. READ MORE

About Sienna

Sienna is a medical technology company focussed on the development and commercialisation of novel IVD (in vitro diagnostic) tests. Sienna manufactures IVD products for pathology laboratories to use in their menu of testing services. Sienna has IVD product registration for their Anti-hTERT Antibody (SCD-A7) in several key markets including the USA, European Union and Australia. READ MORE

Sienna has launched the first ever IVD for detection of telomerase as an adjunct to urine cytology for assisting the diagnosis of bladder cancer.

– CEO, Matthew Hoskin

Contact Sienna

Sienna Cancer Diagnostics

1 Dalmore Drive Scoresby VIC 3179 Australia

Telephone +61 3 8288 2141 Facsimile +61 3 8288 2059